Ho Joon Im

Ho Joon Im

Auto-generated profile, based on publicly available information

Ho Joon Im

Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
HIHo Joon Im
Ho Joon Im
KKKyung Nam Koh
Kyung Nam Koh
ECEun Seok Choi
Eun Seok Choi
SJSeongsoo Jang
Seongsoo Jang
SKSeog Woon Kwon
Seog Woon Kwon
JSJong Jin Seo
Jong Jin Seo
We evaluated the outcome of children and adolescents with acquired severe aplastic anemia (SAA) who received haploidentical hematopoietic stem cell transplantation (HHCT) with in vitro T cell-depleted peripheral blood stem cells. Twelve patients with acquired SAA received a total of 15 HHCTs with in vitro CD3-depleted grafts between July 2009 and July 2012. Among the 12 patients, 11 achieved neutrophil engraftment at a median of 10 days (range, 9 to 13 days) after HHCT. One patient failed to achieve primary engraftment, and two experienced graft rejection soon after engraftment. All three patients who experienced early graft failure received a second HHCT and achieved sustained engraftment. Thus, the final engraftment rate was 100%. Acute graft-versus-host disease was assessed in 9 patients, excluding the 3 patients with early graft failure. Three of these patients developed acute graft-versus-host disease (two ≥ grade II and one with grade III). All 12 patients survived and were transfusion-independent at a median follow-up of 14.3 months (range, 4.1 to 40.7 months). Hematopoietic stem cell transplantation from haploidentical family donors with in vitro CD3 T cell depletion is a reasonable therapeutic option for children and adolescents with acquired SAA. Our future trial with a uniform protocol will help to solve the problems associated with HHCT and provide a valuable platform for the further development of HHCT as a therapy for SAA.

7 October 2009 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
HYHoi Soo Yoon
Hoi Soo Yoon
JLJae Hee Lee
Jae Hee Lee
ECEun Soek Choi
Eun Soek Choi
JSJong Jin Seo
Jong Jin Seo
HMHyung Nam Moon
Hyung Nam Moon
HIHo Joon Im
Ho Joon Im

1 January 2015 in Korean Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
HIHo Joon Im
Ho Joon Im
KKKyung-Nam Koh
Kyung-Nam Koh
JSJong Jin Seo
Jong Jin Seo
Severe aplastic anemia (SAA) is a life-threatening disorder for which allogeneic hematopoietic stem cell transplantation (HSCT) is the current available curative treatment. HSCT from matched sibling donors (MSDs) is the preferred therapy for children with acquired SAA. For patients who lack MSDs, immunosuppressive therapy (IST) is widely accepted as a first-line treatment before considering HCT from an unrelated donor (URD). Given the recent progress in HSCT using URDs for childhood SAA, well-matched URDs became a realistic alternative for pediatric patients who have no suitable related donors and who are refractory to IST. However, it is quite challenging to treat patients with refractory SAA who lack suitable related or URDs. Even though haploidentical HSCT from genetically mismatched family members seemed to be an attractive procedure with the amazing benefit of readily available donors for most patients, early attempts were disappointing because of refractory graft-versus-host disease (GVHD) and excessively high transplant-related mortality. Recent advances with effective ex vivo depletion of T cells or unmanipulated in vivo regulation of T cells, better supportive care, and optimal conditioning regimens have significantly improved the outcome of haploidentical transplant. Besides considerable progress in the treatment of malignant diseases, recent emerging evidences for haploidentical HSCT in SAA has provided additional therapeutic options for patients with refractory diseases. Further improvements to decrease the rates of graft failure, GVHD, and infectious complications will facilitate the emergence of haploidentical HSCT as a front-line therapy for treating acquired SAA in children and adolescents who have no suitably matched donors.

1 January 2006 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JSJoon Sup Song
Joon Sup Song
JSJong Jin Seo
Jong Jin Seo
HMHyung Nam Moon
Hyung Nam Moon
TGThad Ghim
Thad Ghim
HIHo Joon Im
Ho Joon Im
Song JS, et al. J Korean Med Sci. 2006 Oct;21(5):897-903. http://dx.doi.org/10.3346/jkms.2006.21.5.897

1 January 2010 in The Korean Journal of Hematology
Verified
Journal Article
Open access
PDF file
KKKyung Nam Koh
Kyung Nam Koh
MPMeerim Park
Meerim Park
BKBo Eun Kim
Bo Eun Kim
HIHo Joon Im
Ho Joon Im
JSJong Jin Seo
Jong Jin Seo
Koh KN, et al. Korean J Hematol. 2010 Sep;45(3):164-170. http://dx.doi.org/10.5045/kjh.2010.45.3.164

1 November 2017 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MPMeerim Park
Meerim Park
HIHo Joon Im
Ho Joon Im
YLYu‐Jin Lee
Yu‐Jin Lee
NPNuree Park
Nuree Park
SJSeongsoo Jang
Seongsoo Jang
JSJong Jin Seo
Jong Jin Seo